This study is looking at SPN-817, an oral capsule, for adults aged 18 to 70 who have epilepsy that hasn't responded well to other treatments (treatment-resistant epilepsy). The main goal is to see how safe SPN-817 is and how well people tolerate it over 72 weeks. You may be able to join if you have treatment-resistant epilepsy. The study is currently enrolling about 60 participants, but the exact status is unclear.

Study design

This is a multicenter, open-label study, meaning both you and the study team will know what treatment you are receiving. It plans to enroll about 60 participants.

What's involved

You would go through a screening period of up to 8 weeks, followed by a 9-week titration period and a 12-week maintenance period. There's also an optional extension period of up to 52 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary safety and tolerability effects are measured at 72 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.